1-20 of 45
Matthew Mei
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Clinical Trials & Observations
Matthew Mei, Lu Chen, James Godfrey, Joo Song, Colt Egelston, Sandrine Puverel, L. Elizabeth Budde, Saro Armenian, Liana Nikolaenko, Mary Nwangwu, Weihua Guo, Lei Gao, Peter Lee, Robert Chen, Shari Daniels, Neena Kennedy, Lacolle Peters, Jasmine Zain, Steven Rosen, Stephen Forman, Leslie Popplewell, Larry Kwak, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (16): 1359–1370.
https://doi.org/10.1182/blood.2023020485
Published: 2023
Includes: Supplemental data
Journal Articles

The next frontier: enter PD-1 and exit PET scans?

Clinical Trials & Observations
Matthew Mei, Alex F. Herrera
Journal: Blood
Blood (2023) 141 (21): 2545–2546.
https://doi.org/10.1182/blood.2023020326
Published: 2023
Journal Articles

Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

Karamjeet S. Sandhu, Alan Macias, Marissa Del Real, Asuscena L. Beltran, Young Sun Kim, Jianying Zhang, Joycelynne Palmer, Marjorie Robbins, Reyna Loomis, Mojtaba Akhtari, Ahmed Aribi, Shukaib Arslan, Amandeep Salhotra, Matthew Mei, Hoda Pourhassan, Paul B. Koller, Idoroenyi Amanam, Vaibhav Agrawal, Peter T. Curtin, Ricardo Spielberger, Vinod A. Pullarkat, Ibrahim Aldoss, F. Mark Stewart, Eileen P. Smith, Stephen J Forman, Anthony S. Stein, Guido Marcucci, L. Elizabeth Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 8985–8986.
https://doi.org/10.1182/blood-2022-170279
Published: 2022
Journal Articles

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Reid W Merryman, Robert A. Redd, Arnold S. Freedman, Inhye E. Ahn, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Eric D Jacobsen, Austin I. Kim, Ann S. LaCasce, Samuel Ng, Oreofe O. Odejide, Erin Michelle Parry, Iris Isufi, Justin Kline, Jonathon B. Cohen, Neha Mehta-Shah, Nancy L. Bartlett, Matthew Mei, Philippe Armand, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 6531–6533.
https://doi.org/10.1182/blood-2022-159823
Published: 2022
Journal Articles

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Stephen E. Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, Philip A. Thompson, Michael Y. Choi, Avyakta Kallam, Sirou Wang, Uzor C. Ogbu, Akash Nahar, Michael L. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6640–6641.
https://doi.org/10.1182/blood-2022-163509
Published: 2022
Journal Articles

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Matthew Mei, Sairah Ahmed, Amer Beitinjaneh, Natalie S. Grover, Carlos A. Ramos, Khong Bee Kang, Paul I. Nadler, Aung Myo, Ivan D. Horak, Helen E. Heslop
Journal: Blood
Blood (2022) 140 (Supplement 1): 12728–12730.
https://doi.org/10.1182/blood-2022-157131
Published: 2022
Journal Articles

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

David M. Kurtz, Sairah Ahmed, Cheuk Ka Tong, Matthew Mei, Cliff Ding, Ian W. Flinn, Peter A. Riedell, Gregory J. Hogan, Andre Schultz, Jacob J. Chabon, Helen E. Heslop, Aung Myo, Ash A. Alizadeh, Ivan D. Horak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2378–2380.
https://doi.org/10.1182/blood-2022-162150
Published: 2022
Journal Articles

Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

Swetha Kambhampati, Matthew Mei, Lu Chen, Sandrine Puverel, Robert Chen, Leslie L. Popplewell, Liana Nikolaenko, Lacolle Peters, Saro H. Armenian, Larry W. Kwak, Steve T Rosen, Stephen J Forman, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 9418–9419.
https://doi.org/10.1182/blood-2022-157623
Published: 2022
Journal Articles

Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S. Grover, Renu Balyan, Cliff Ding, Aung Myo, Ivan D. Horak, Helen E. Heslop
Journal: Blood
Blood (2022) 140 (Supplement 1): 7496–7497.
https://doi.org/10.1182/blood-2022-158869
Published: 2022
Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Tamer Othman, Christopher Ruel, Paul Frankel, Alexander A. Merleev, Guillaume Luxardi, Emanual Maverakis, Mehrdad Abedi, Raghuveer Ranganathan, Jasmine Zain, Lihua E Budde, Matthew Mei, Aaron S Rosenberg, Rasmus T Hoeg, Caitlin Costello, Francine M. Foss, Basem M. William, H. Kent Holland, Miguel Villalona-Calero, Elad Sharon, Joseph M Tuscano
Journal: Blood
Blood (2022) 140 (Supplement 1): 9446–9447.
https://doi.org/10.1182/blood-2022-167173
Published: 2022
Journal Articles

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Tamer Othman, Ibrahim Aldoss, Ni-Chun Tsai, Hoda Pourhassan, Vaibhav Agrawal, Salman Otoukesh, Idoroenyi Amanam, Dat Ngo, Jason Chen, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S. Sandhu, Shukaib Arslan, Brian J Ball, Forrest M. Stewart, Peter T. Curtin, Andrew S. Artz, David S Snyder, Guido Marcucci, Stephen J Forman, Anthony S. Stein, Ryotaro Nakamura, Vinod A. Pullarkat, Matthew Mei, Paul B. Koller
Journal: Blood
Blood (2022) 140 (Supplement 1): 10568–10570.
https://doi.org/10.1182/blood-2022-163652
Published: 2022
Journal Articles

Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Tamer Othman, Paul B. Koller, Ni-Chun Tsai, Hoda Pourhassan, Vaibhav Agrawal, Salman Otoukesh, Idoroenyi Amanam, Dat Ngo, Jason Chen, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S. Sandhu, Shukaib Arslan, Brian J. Ball, Forrest M. Stewart, Peter T. Curtin, Andrew S. Artz, David S. Snyder, Guido Marcucci, Stephen J. Forman, Anthony S. Stein, Ryotaro Nakamura, Vinod A. Pullarkat, Ibrahim Aldoss, Matthew Mei
Journal: Blood
Blood (2022) 140 (Supplement 1): 4821–4822.
https://doi.org/10.1182/blood-2022-164639
Published: 2022
Journal Articles

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Matthew Mei, Joycelynne Palmer, Ni-Chun Tsai, Hun Ju Lee, Iris Isufi, Leslie L. Popplewell, Lynne Smith, Lacolle Peters, Lara Rodriguez, James Godfrey, John H. Baird, Joo Y. Song, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 774–776.
https://doi.org/10.1182/blood-2022-167626
Published: 2022
Journal Articles

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Tamer Othman, Paul B. Koller, Ni-Chun Tsai, Hoda Pourhassan, Vaibhav Agrawal, Salman Otoukesh, Idoroenyi Amanam, Dat Ngo, Jason Chen, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S. Sandhu, Shukaib Arslan, Brian J Ball, Forrest M. Stewart, Peter T. Curtin, Andrew S. Artz, David S Snyder, Guido Marcucci, Stephen J Forman, Anthony S. Stein, Ryotaro Nakamura, Vinod A. Pullarkat, Ibrahim Aldoss, Matthew Mei
Journal: Blood
Blood (2022) 140 (Supplement 1): 12819–12820.
https://doi.org/10.1182/blood-2022-164657
Published: 2022
Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Alex F. Herrera, Lu Chen, Jennifer L. Crombie, Jonathon B. Cohen, Ranjana H. Advani, Ann S. LaCasce, Leslie L. Popplewell, Sandrine Puverel, Lacolle Peters, Shari Daniels, James Godfrey, Geoffrey Shouse, Matthew Mei, Swetha Kambhampati, L. Elizabeth Budde, Liana Nikolaenko, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Matthew J. Matasar
Journal: Blood
Blood (2022) 140 (Supplement 1): 1065–1067.
https://doi.org/10.1182/blood-2022-165699
Published: 2022
Journal Articles

The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Matthew Mei, Raju Pillai, Soyoung Kim, Noel Estrada-Merly, Michelle Afkhami, Lixin Yang, Zhuo Meng, Ronald M. Sobecks, Betul Oran, Bart L. Scott, Wael Saber, Ryotaro Nakamura
Journal: Blood
Blood (2021) 138 (Supplement 1): 417.
https://doi.org/10.1182/blood-2021-146673
Published: 2021
Journal Articles

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Alex F. Herrera, Jasmine Zain, Kerry J. Savage, Tatyana A. Feldman, Jonathan E Brammer, Lu Chen, Leslie L. Popplewell, Lihua E Budde, Matthew Mei, Lori A. Leslie, Ranjit Nair, Chitra Hosing, Lacolle Peters, Stephen J Forman, Steven T. Rosen, Larry W. Kwak, Swaminathan P Iyer
Journal: Blood
Blood (2021) 138 (Supplement 1): 133.
https://doi.org/10.1182/blood-2021-151105
Published: 2021
Journal Articles

Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade

Alex F. Herrera, Lu Chen, L. Elizabeth Budde, Saro Armenian, Liana Nikolaenko, Robert Chen, Shari Daniels, Neena Kennedy, Lacolle Peters, Steven T. Rosen, Stephen J Forman, Leslie L. Popplewell, Larry W. Kwak, Matthew Mei
Journal: Blood
Blood (2021) 138 (Supplement 1): 234.
https://doi.org/10.1182/blood-2021-150031
Published: 2021
Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon
Journal: Blood
Blood (2021) 138 (Supplement 1): 528.
https://doi.org/10.1182/blood-2021-148607
Published: 2021
Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Steven M. Horwitz, James M. Foran, Michael Maris, Jennifer Kimberly Lue, Ahmed Sawas, Craig Okada, Tatyana A. Feldman, Lubomir Sokol, Matthew Mei, Ian W. Flinn, Diego Villa, Mary-Elizabeth M. Percival, Deepa Jagadeesh, Kerry J. Savage, Oleg Akilov, Catherine S. Diefenbach, Youn H. Kim, Gloria H. Y. Lin, Tina Catalano, Penka S. Petrova, Bob Uger, Naomi Molloy, Kathleen Large, Ingmar Bruns, Stephen M. Ansell
Journal: Blood
Blood (2021) 138 (Supplement 1): 2448.
https://doi.org/10.1182/blood-2021-154490
Published: 2021